Lunit

Lunit is a global medical AI software company dedicated to conquering cancer through cutting-edge artificial intelligence. Founded in 2013 and headquartered in Korea, Lunit has grown from a small engineering team into a worldwide cancer AI ecosystem, with its solutions adopted by more than 10,000 medical institutions across 65+ countries. Backed by 700+ publications and 100+ partnerships, Lunit transforms complex clinical imaging and pathology data into clear, actionable insights that empower earlier cancer detection and more precise treatment decisions across the full care pathway.

Lunit's platform-based approach connects imaging, pathology, and biomarker intelligence through a modular, interoperable ecosystem. Trained on diverse global datasets and built for scalability, its AI models integrate seamlessly into real-world clinical and biopharma workflows — spanning cancer screening, diagnosis, treatment planning, and drug development. The company collaborates with healthcare providers, life science companies, and technology leaders united by a shared mission to redefine how the world fights cancer.

Cancer Screening Products

• Lunit INSIGHT MMG (2D) — AI-powered mammography analysis for 2D breast cancer screening, FDA-cleared, CE-marked under EU MDR, and cleared by Korea's Ministry of Food and Drug Safety, enabling detection of the smallest cancers that may otherwise be missed.
• Lunit INSIGHT DBT (3D) — A 3D digital breast tomosynthesis screening product, launched with CE mark under EU MDR, extending AI-assisted detection to advanced breast imaging modalities.
• Lunit INSIGHT CXR — AI analysis for chest X-rays, including a triage function with FDA clearance and CE mark, and recommended by the World Health Organization as a diagnostic tool for tuberculosis screening.
• Live Analytics & Scorecard — Real-time performance monitoring tools that provide operational intelligence across screening programs.
• Patient Hub & Risk Pathways — Connected ecosystem tools that streamline patient management and support risk-stratified clinical decision-making.

Precision Oncology Products

• Lunit SCOPE IO — TME Analysis — AI-driven analysis of the tumor microenvironment (TME), delivering deep biomarker intelligence from digital pathology images at unprecedented speed and scale.
• Lunit SCOPE IHC Suite — IHC Quantification — A suite of immunohistochemistry (IHC) quantification tools including:
  • Lunit SCOPE uIHC — Universal IHC analysis for a broad range of biomarkers.
  • Lunit SCOPE HER2 — AI-powered HER2 scoring, demonstrated to achieve high concordance with pathologists in HER2 interpretation for advanced biliary tract cancer.
  • Lunit SCOPE PD-L1 — CE-marked PD-L1 quantification, powering the Guardant360 TissueNext PD-L1 test in collaboration with Guardant Health.
• Lunit SCOPE GP — Genotype Prediction — AI-based prediction of genomic features from histopathology images, supporting biomarker discovery and companion diagnostic (CDx) strategy.

Biopharma and Clinical Trial Solutions

• Lunit partners with biopharma companies to accelerate oncology innovation from discovery through companion diagnostics, offering AI intelligence solutions purpose-built for clinical trials and global deployment.
• Strategic collaborations include a partnership with AstraZeneca and a collaboration with CellCarta to accelerate AI-enabled digital pathology for companion diagnostic programs.
• Lunit's precision oncology tools support biomarker development, CDx strategy, and real-world evidence generation at scale.

Technology Platform and Integration

• Lunit's modular platform connects multimodal data across imaging and pathology, enabling seamless interoperability with existing clinical workflows.
• The platform is designed to evolve toward foundation models, supporting the next generation of cancer AI.
• Radiology technology and integration partnerships span industry leaders including Fujifilm, GE Healthcare, Philips, Agfa, and Microsoft, streamlining workflow integration and elevating patient care.
• A partnership agreement with the U.S. National Cancer Institute further underscores Lunit's commitment to advancing cancer research at a global level.

Regulatory Approvals and Recognition

• FDA clearances for Lunit INSIGHT MMG, Lunit INSIGHT CXR Triage, and CXR-AID (developed with Fujifilm, with PMDA approval in Japan).
• CE marks under EU MDR for Lunit INSIGHT MMG, Lunit INSIGHT CXR, Lunit INSIGHT DBT, Lunit INSIGHT CXR4, and Lunit SCOPE PD-L1.
• Clearances from Korea's Ministry of Food and Drug Safety for Lunit INSIGHT MMG and Lunit INSIGHT CXR-Nodule.
• Named a World Economic Forum Technology Pioneer 2020, and subsequently joined the WEF as an Associate Partner — the first medical AI company to advance from Technology Pioneer status.
• Recommended by the WHO as a diagnostic tool for tuberculosis screening.
• Multiple appearances on CB Insights' Digital Health 150 and recognition as a Top 5 Social Impact AI Startup by NVIDIA.
• Completed an Initial Public Offering on KOSDAQ and has secured multiple rounds of funding from investors including SoftBank Ventures Asia, Fujifilm, Guardant Health, HealthQuest, and Naver.

With a mission to conquer cancer together through the power of AI — boldly, intelligently, and with humanity at the core — Lunit continues to expand its global footprint, deepen its partnerships, and push the boundaries of what medical AI can achieve across the full cancer continuum.